Multisystem inflammatory syndrome in children: A dysregulated autoimmune disorder following COVID-19.
J Microbiol Immunol Infect
; 56(2): 236-245, 2023 Apr.
Article
in English
| MEDLINE | ID: covidwho-2298597
ABSTRACT
Multisystem inflammatory syndrome in children (MIS-C) is a dysregulated autoimmune-mediated illness in genetically susceptible patients following COVID-19 with an interval of 2-6 weeks. The median age of patients with MIS-C is 6-11 years. Most common manifestations are involvement of gastrointestinal tract, cardiovascular system, hematological system, and mucocutaneous system. Respiratory tract, neurological system, musculoskeletal system, and kidney are less frequently affected. Mucocutaneous manifestations and coronary artery abnormalities characteristic for Kawasaki disease (KD) may be observed in a significant proportion of MIS-C patients that may make the differential diagnosis be difficult for some patients, especially in the post-pandemic era. The mortality rate is 1-3%. Management and prognosis of MIS-C are similar to that of KD. MIS-C and KD may share a common pathogenic process. Based on the observation of MIS-C-like illness in uninfected neonates, i.e. multisystem inflammatory syndrome in neonates, both MIS-C and KD may be a consequence of dysregulated, over-exaggerated humoral immune responses triggered by a specific infectious agent.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Autoimmune Diseases
/
COVID-19
/
Mucocutaneous Lymph Node Syndrome
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Child
/
Humans
/
Infant, Newborn
Language:
English
Journal:
J Microbiol Immunol Infect
Journal subject:
Allergy and Immunology
/
Microbiology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS